Italia markets closed

CELU May 2024 5.000 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,25000,0000 (0,00%)
In data: 02:58PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente1,2500
Aperto1,2500
Denaro0,0000
Lettera3,4000
Prezzo d'esercizio5,00
Scadenza2024-05-17
Min-Max giorno1,2500 - 1,2500
Contratto - Min-MaxN/D
Volume3
Open Interest25
  • GlobeNewswire

    Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

    Pharmaceutical and Academic Veteran Brings Significant Innovative Technology and Development Expertise Launching New Cellular TherapiesFLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors. Dr. Ling, a distinguished academic and

  • GlobeNewswire

    Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron

    Celularity to provide research support for Regeneron's targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapyAgreement underscores Celularity's demonstrated expertise in cell therapy research FLORHAM PARK, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals, Inc.

  • GlobeNewswire

    Celularity Inc. Announces $3 Million Registered Direct Offering

    FLORHAM PARK, N.J., July 27, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 8,571,428 shares of its Class A common stock together with warrants to purchase up to 8,571,428 shares of its Class A common stock at a combined